Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

BRD4: An emerging prospective therapeutic target in glioma
Hua Yang, Li Wei, Yang Xun, et al.
Molecular Therapy — Oncolytics (2021) Vol. 21, pp. 1-14
Open Access | Times Cited: 37

Showing 1-25 of 37 citing articles:

Regulation of programmed cell death by Brd4
Jinfeng Hu, Dun Pan, Guo Li, et al.
Cell Death and Disease (2022) Vol. 13, Iss. 12
Open Access | Times Cited: 47
BET bromodomain inhibition rescues PD-1-mediated T-cell exhaustion in acute myeloid leukemia
Mengjun Zhong, Rili Gao, Ruocong Zhao, et al.
Cell Death and Disease (2022) Vol. 13, Iss. 8
Open Access | Times Cited: 40
Facioscapulohumeral muscular dystrophy: the road to targeted therapies
Mara S. Tihaya, Karlien Mul, Judit Balog, et al.
Nature Reviews Neurology (2023) Vol. 19, Iss. 2, pp. 91-108
Closed Access | Times Cited: 36
ByeTAC: Bypassing an E3 Ligase for Targeted Protein Degradation
Eslam M.H. Ali, Cody A. Loy, Darci J. Trader
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 10
Crosstalk between PI3K/AKT/mTOR and WNT/β-Catenin signaling in GBM - Could combination therapy checkmate the collusion?
Daisy S Precilla, Indrani Biswas, Shreyas S. Kuduvalli, et al.
Cellular Signalling (2022) Vol. 95, pp. 110350-110350
Closed Access | Times Cited: 36
Efficient Anti-Glioma Therapy Through the Brain-Targeted RVG15-Modified Liposomes Loading Paclitaxel-Cholesterol Complex
Xin Xin, Wei Liu, Zheao Zhang, et al.
International Journal of Nanomedicine (2021) Vol. Volume 16, pp. 5755-5776
Open Access | Times Cited: 34
The role of protein acetylation in carcinogenesis and targeted drug discovery
Jingru Yang, Cong Song, Xianquan Zhan
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 27
Enhanced anti-glioma efficacy of doxorubicin with BRD4 PROTAC degrader using targeted nanoparticles
Yihong He, Xin Zan, Junming Miao, et al.
Materials Today Bio (2022) Vol. 16, pp. 100423-100423
Open Access | Times Cited: 22
Hydrogen Peroxide‐Inducible PROTACs for Targeted Protein Degradation in Cancer Cells
Dehao Yu, Heli Fan, Zhili Zhou, et al.
ChemBioChem (2023) Vol. 24, Iss. 17
Open Access | Times Cited: 12
Advancing brain tumor therapy: unveiling the potential of PROTACs for targeted protein degradation
S.M. Ibrahim, Muhammad Umer Khan, Saadia Noreen, et al.
Cytotechnology (2025) Vol. 77, Iss. 2
Closed Access
The multifaceted role of Sestrin 3 (SESN3) in oxidative stress, inflammation and tumorigenesis
Qian Chen, Guoqiang Zhong, Xiao-qun Fang, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research (2025), pp. 119938-119938
Closed Access
ByeTAC: Bypassing E-Ligase-Targeting Chimeras for Direct Proteasome Degradation
Cody A. Loy, Eslam M.H. Ali, Laurence J. Seabrook, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, “window-of-opportunity” study
Víctor Moreno, Juan Manuel Sepúlveda-Sánchez, David A. Reardon, et al.
Neuro-Oncology (2022) Vol. 25, Iss. 6, pp. 1113-1122
Open Access | Times Cited: 18
Proteolysis-Targeting Chimera (PROTAC): Is the Technology Looking at the Treatment of Brain Tumors?
Ludovica Lospinoso Severini, Francesca Bufalieri, Paola Infante, et al.
Frontiers in Cell and Developmental Biology (2022) Vol. 10
Open Access | Times Cited: 16
BRD2‐specific inhibitor, BBC0403, inhibits the progression of osteoarthritis pathogenesis in osteoarthritis‐induced C57BL/6 male mice
Hyemi Lee, Jiho Nam, Hahyeong Jang, et al.
British Journal of Pharmacology (2024) Vol. 181, Iss. 15, pp. 2528-2544
Open Access | Times Cited: 3
Dual BET/HDAC inhibition to relieve neuropathic pain: Recent advances, perspectives, and future opportunities
Maria Novella Romanelli, Vittoria Borgonetti, Nicoletta Galeotti
Pharmacological Research (2021) Vol. 173, pp. 105901-105901
Closed Access | Times Cited: 19
Discovery of novel BRD4-BD2 inhibitors via in silico approaches: QSAR techniques, molecular docking, and molecular dynamics simulations
Jianbo Tong, Xuechun Xiao, Ding Luo, et al.
Molecular Diversity (2023) Vol. 28, Iss. 2, pp. 671-692
Closed Access | Times Cited: 7
Novel molecule BBC0901 inhibits BRD4 and acts as a catabolic regulator in the pathogenesis of osteoarthritis
Hye‐Mi Lee, Jiho Nam, Hahyeong Jang, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 166, pp. 115426-115426
Open Access | Times Cited: 7
Systemically intravenous siRNA delivery into brain with a targeting and efficient polypeptide carrier and its evaluation on anti-glioma efficacy
Liqing Chen, Zheming Zhang, Yanhong Liu, et al.
Chinese Chemical Letters (2024), pp. 110228-110228
Closed Access | Times Cited: 2
Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma
María Vieito, Matteo Simonelli, Filip De Vos, et al.
Neuro-Oncology Advances (2022) Vol. 4, Iss. 1
Open Access | Times Cited: 11
Comprehensive analysis of the prognosis and immune infiltrates for the BET protein family reveals the significance of BRD4 in glioblastoma multiforme
Yintao Ye, Wei Zhong, Junqiang Qian, et al.
Frontiers in Cell and Developmental Biology (2023) Vol. 11
Open Access | Times Cited: 5
Epigenetic instability may alter cell state transitions and anticancer drug resistance
Anshul Saini, James M. Gallo
PLoS Computational Biology (2021) Vol. 17, Iss. 8, pp. e1009307-e1009307
Open Access | Times Cited: 11
Novel BRD4-p53 Inhibitor SDU-071 Suppresses Proliferation and Migration of MDA-MB-231 Triple-Negative Breast Cancer Cells
Shumei Wang, Kang Lei, Hsien‐Tsung Lai, et al.
ACS Pharmacology & Translational Science (2024) Vol. 7, Iss. 4, pp. 1178-1190
Closed Access | Times Cited: 1
2,2’- Bipyridine Derivatives Exert Anticancer Effects by Inducing Apoptosis in Hepatocellular Carcinoma (HepG2) Cells
Priyanka, Somdutt Mujwar, Ram Suresh Bharti, et al.
Journal of Hepatocellular Carcinoma (2024) Vol. Volume 11, pp. 2181-2198
Open Access | Times Cited: 1
Substituted 2,3-Benzodiazepines Derivatives as Bromodomain BRD4 Inhibitors
Ram W. Sabnis
ACS Medicinal Chemistry Letters (2021) Vol. 12, Iss. 10, pp. 1530-1531
Open Access | Times Cited: 10
Page 1 - Next Page

Scroll to top